 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || cerdulatinib topical (DMVT-502) / Roivant, Opzelura (ruxolitinib cream) / Incyte, Maruho
Review, Journal: Efficacy and Safety of Topical JAK inhibitors in the Treatment of Atopic Dermatitis in Pediatrics and Adults: A Systematic Review. (Pubmed Central) - Jan 25, 2023
Available topical JAKi are effective and safe modalities in treating AD. Nevertheless, further studies with longer duration and head-to-head comparative trials are necessary to find the best option with the least adverse effects.
- || cerdulatinib topical (DMVT-502) / Roivant
Clinical, P1 data, Journal: A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis. (Pubmed Central) - Nov 25, 2021
Nevertheless, further studies with longer duration and head-to-head comparative trials are necessary to find the best option with the least adverse effects. No abstract available
- || cerdulatinib topical (DMVT-502) / Roivant
Trial completion, Trial completion date, Trial primary completion date: Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo (clinicaltrials.gov) - Nov 24, 2020
P2a, N=33, Completed, Sponsor: Dermavant Sciences GmbH
No abstract available Recruiting --> Completed | Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Nov 2020
- | cerdulatinib topical (DMVT-502) / Roivant
New P2a trial: Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo (clinicaltrials.gov) - Sep 24, 2019
P2a, N=30, Recruiting, Sponsor: Dermavant Sciences GmbH